Treatment of Intracranial Infection by Extensively Drug-Resistant Acinetobacter Baumannii After Craniocerebral Surgery.

OBJECTIVE

The clinical outcome of intracranial infections caused by extensively drug-resistant Acinetobacter baumannii (XDRAB) remains unsatisfactory, even when treated with combined antibiotic therapy. This study successfully cured 1 patient with XDRAB intracranial infection after cranial surgery through a multichannel combination of drugs, providing a reference for the clinical treatment of severe XDRAB intracranial infection.

METHODS

The clinical data of a patient with an XDRAB intracranial infection after a craniocerebral operation were retrospectively analyzed, and the treatment approach for XDRAB intracranial infection was examined.

RESULTS

Upon the occurrence of XDRAB intracranial infection after craniocerebral surgery, the patient was given an intravenous injection of polymyxin B+ tigecycline + amikacin, while intrathecal injection of polymyxin B, and the intracranial infection was controlled and cured.

CONCLUSIONS

Polymyxin B+ tigecycline + amikacin intravenous and intrathecal polymyxin B can benefit XDRAB intracranial infected patients after craniofacial surgery.